 rais solid initi
guid includ recent see organ subscript
growth least
veeva report anoth beat rais quarter even account
impact commerci vault notabl achiev commerci
gain market share vault cdm roll larg phase trial
demonstr veeva readi prime time still nascent offer
guidanc somewhat muddi given consolid contribut
two recent acquisit estim subscript revenu continu
grow y/i expect modest margin dilut acquisit
revers cours
highlight quarter confer call
commerci cloud continu see success segment track
y/i acceler growth recogn prior
year attribut perform broaden product offer
market share expans event manag call
see particular strength quarter expect event manag
reinforc physician world acquisit allow
close loop bolster exist softwar servic solut
gain share segment buy call
anti-competit pressur toward andi nitro offer
see potenti advers increment growth opportun
veeva would note veeva offer unaffect new
exist client continu bring prescription/sal data
believ substanti curtail risk disrupt exist revenu
new commerci cloud revenu growth outsid andi/nitro
product moreov note strong demand opendata solut
compet onekey offer highlight top pharma
select opendata use domest two top pharma
roll opendata countri
vault also appear build momentum continu see
adopt across vault suit continu view vault key
growth driver veeva us highlight quarter large-
scale phase announc surpris happen
surpris happen earli cdm life cycl think
announc loud vote confid import foundat drive
futur adopt cdm note cdm alon address
factor better expect organ perf
factor better expect organ perf
dilut effect acquir compani
tr target
strh consenu figur restat
except consensu ebitda figur
adjust one time tax benefit
ex-lif scienc gain traction veeva note activ discuss top cpg
compani think veeva still year meaning revenu contribut
segment think good sign qualiti regulatori suit ex-lif
updat estim initi guidanc introduc estim
factor updat guidanc estim track recogn y/i
organ growth recent acquisit crossix physician world slightli dilut margin
believ bolster veeva suit product instrument help drive increment
growth commerci cloud segment model revenu
half increas prior estim driven organ factor half
 rais estim approxim driven
 balanc organ introduc estim impli y/i growth
driven growth subscript mid-teen growth profession servic
expect non-gaap op margin dip due dilut impact
 recogn driven improv margin scale oper leverag
pt pt impli ev/fcf introduc estim multipl in-lin
year averag ntm ev/fcf multipl warrant view given
continu beat rais market share gain continu introduct differenti new
product could fuel next leg growth
page
page
svc ebitda impli ev/revenu impli ev/ebitda impli strh research factset veevstrh pt high/low rangesourc factset compani data strh research veeva system inc
page
sandi draper statement y/i gross gross margin oper oper oper margin incom expens incom provis incom tax net incom attrib class dilut stock y/i net non-gaap net non-gaap y/i gp opnon-gaap gross non-gaap gross margin oper expens y/i oper non-gaap oper magin y/i non-gaap non-gaap ebitda y/i subscript y/i y/i strh research compani data figur present non-gaap basi ticker veeva
veeva found predominantli provid saas-bas cloud solut target
life scienc industri product servic primarili design support sale market
research develop effort life scienc client commerci cloud
vault product suit start serv custom employ peopl
although serv largest pharmaceut biotechnolog custom global
one client account revenu sinc go public
find share attract rate stock buy given larg expand bil
solid technolog platform product develop consist financi execut think
veeva potenti achiev scale combin gain market share increas
penetr within client base expand address market new solut enter
vertic outsid life scienc
valuat risk
pt pt weight averag scenario analysi support dcf base
appli probabl low-cas pt ev/fcf mid-cas
pt ev/fcf high-cas pt ev/fcf high-
low- multipl scenario analysi approxim year high- low- ntm ev/fcf
multipl pt impli ev/fcf multipl estim in-lin year
averag multipl believ warrant given continu beat rais market
share gain acceler subscript revenu growth recent trend market share gain
pharma win cdm well med devic win continu introduct
differenti new product could fuel next leg growth
risk rate price target manag expand margin remain high-growth
compani increas competit dassault system medidata iqvia entranc new
vertic market multipl
compani mention note
sandi draper herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
